Tag: regulatory inspection readiness

Best Practices in Preventing Data Manipulation in Stability Testing

In pharmaceutical stability testing, data integrity is paramount—not just for regulatory compliance, but to ensure that patients receive safe and effective medications. One of the most critical threats to this integrity is data manipulation, whether accidental or deliberate. This article presents best practices to prevent such occurrences and maintain trust in your stability data. 📈…

Best Practices for Stability Testing Data Integrity, Pharmaceutical Quality and Practices

Training Stability Analysts on Deviation Investigation and CAPA

Deviation investigation and CAPA (Corrective and Preventive Actions) management are critical components in the pharmaceutical quality system. For stability studies, even a minor deviation can impact long-term product safety, shelf life, or regulatory compliance. That’s why training stability analysts on handling such events is not optional—it’s essential. This tutorial outlines best practices for training stability…

Handling Deviations and CAPA in Stability Reports, Protocols and Reports

ICH Q1E Data Use in Re-Test Period Justification

In pharmaceutical manufacturing, the re-test period is a critical parameter for active pharmaceutical ingredients (APIs) and certain drug products. Regulatory authorities expect this period to be scientifically justified using robust stability data. This article walks you through how to use ICH Q1E guidelines to justify re-test periods, ensuring your submission aligns with global expectations. 💡…

ICH Q1E and Stability Data Evaluation, Protocols and Reports

Data Governance Tools Used in Regulatory-Compliant Stability Programs

In the pharmaceutical industry, stability studies generate large volumes of critical data used to determine product shelf life, quality, and regulatory viability. However, simply collecting this data is not enough. It must be governed, managed, and protected using compliant systems that align with ALCOA+ and GxP principles. Enter data governance tools. These tools play a…

Regulatory Guidelines, Significant Changes and Data Integrity Compliance

Using Audit Trails to Support Data Integrity Compliance

Audit trails are a core component of data integrity compliance in pharmaceutical manufacturing and testing. In the eyes of regulatory agencies like the USFDA, EMA, and CDSCO, audit trails provide the transparency required to prove that data was recorded accurately, honestly, and in real-time. With increasing reliance on computerized systems — from LIMS to CDS…

Regulatory Guidelines, Significant Changes and Data Integrity Compliance

How to Document Protocol Amendments in Long-Term Stability Studies

Protocol amendments are inevitable during long-term pharmaceutical stability studies. Whether due to updated regulatory expectations, analytical method improvements, or internal corrective actions, changes to the protocol must be handled with the utmost care. This how-to guide outlines the correct way to document such amendments while ensuring full compliance with ICH guidelines, preserving data integrity, and…

Regulatory Guidelines, Significant Changes and Data Integrity Compliance

Best Practices for Record Keeping in GMP Environments

In the realm of Good Manufacturing Practices (GMP), documentation is considered evidence of compliance. For pharmaceutical companies, especially those conducting long-term stability studies, proper record keeping is critical to ensuring product quality, data integrity, and regulatory readiness. Regulatory agencies such as the USFDA, WHO, and EMA frequently cite poor documentation practices as a leading cause…

Good Manufacturing Practices (GMP) for Stability Studies, Pharmaceutical Quality and Practices

Lifecycle Approach to Global Stability Testing Compliance

Pharmaceutical stability testing is not a one-time activity restricted to pre-approval stages. Instead, it follows a comprehensive lifecycle approach—extending from early development through post-approval surveillance—to ensure consistent product quality over time. This regulatory-focused article explores how companies can align their global stability testing efforts with lifecycle principles, complying with agencies such as USFDA, EMA, WHO,…

Global Harmonization of Stability Testing Regulations, Regulatory Guidelines